Author

I. Dolgalev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. G. Neel· 3 shared D. A. Levine· 2 shared H. Ran· 2 shared A. Heguy· 1 shared A. Koide· 1 shared A. Patel· 1 shared A. Rao· 1 shared A. Tsirigos· 1 shared

Activity by Year

2018-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. G. Neel

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Genome-wide CRISPR/Cas9 Screens Reveal Shared and Bespoke Mechanisms of Resistance to SHP2 inhibition

W. Wei, M. J. Geer, X. Guo, I. Dolgalev, N. E. Sanjana, B. G. Neel

This study identifies genes conferring resistance to SHP2 inhibitors through CRISPR screens and shows their roles in reactivating ERK signaling in cancer cells.

bioRxiv · Aug 26, 2022 · PreprintCancer Biology

Drug-induced adaptation along a resistance continuum in cancer cells

G. S. Franca, M. Baron, M. Pour, B. R. King, A. Rao, S. Misirlioglu, D. Barkley, I. Dolgalev, K. Ho-Tang, G. Avital, F. Kuperwaser, A. Patel, D. A. Levine, T. Lionnet, I. Yanai

This study shows that gradual dose exposure and prolonged treatment drive ovarian cancer cell resistance to targeted therapy through a continuous adaptation process involving transcriptional, epigenetic, and genetic changes.

bioRxiv · Jun 21, 2022Cancer Biology

Single-Cell RNA Sequencing Reveals the Effects of Chemotherapy on Human Pancreatic Adenocarcinoma and its Tumor Microenvironment

G. Werba, D. Weissinger, E. A. Kawaler, E. Zhao, D. Kalfakakou, S. Dhara, G. Oh, X. Jing, N. Beri, L. Khanna, T. Gonda, P. Oberstein, C. Hajdu, C. A. Loomis, A. Heguy, , D. M. Simeone

This study uses single-cell RNA sequencing to analyze how chemotherapy affects PDAC tumor cells and their microenvironment, finding limited transcriptional shifts and reduced TIGIT-mediated immune checkpoint activity.

bioRxiv · May 24, 2022Cancer Biology

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors

C. Fedele, S. Li, K. W. Teng, C. Foster, D. Peng, H. Ran, P. Mita, M. Geer, T. Hattori, A. Koide, Y. Wang, K. H. Tang, J. Leinwand, W. Wang, B. Diskin, , B. G. Neel

This study shows that combining SHP2 inhibitors with KRASG12C inhibitors enhances efficacy in PDAC and NSCLC by overcoming resistance and remodeling the tumor microenvironment.

bioRxiv · May 30, 2020Cancer Biology

Both Fallopian Tube and Ovarian Surface Epithelium Can Act as Cell-of-Origin for High Grade Serous Ovarian Carcinoma

B. G. Neel, S. Zhang, T. Zhang, I. Dolgalev, H. Ran, D. A. Levine

This paper shows that both fallopian tube and ovarian surface epithelium can originate high grade serous ovarian carcinoma, with distinct biological properties and therapeutic responses.

bioRxiv · Nov 29, 2018Cancer Biology